Aptevo Therapeutics (APVO) Financials: Revenue & Earnings
APVO$1.34+0.04 +3.08%
$2.93M
Market Cap
—
P/E
—
Forward P/E
—
Score
Aptevo Therapeutics (APVO) Financials: Revenue & Earnings
APVO price $1.34 +0.04 +3.08%
- Ticker
- APVO
- Price
- $1.34
- Change
- +0.04 +3.08%
- Market cap ?
- $2.93M
- Sector
- Healthcare
- Industry
- Biotechnology
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company primarily focused on pioneering immunotherapeutic agents for a variety of cancer treatments across the United States. Its foremost investigational drug, APVO436, is a bispecific antibody crafted to engage T-cells, which is currently undergoing a Phase 1b clinical study for acute myeloid leukemia and myelodysplastic syndromes. Beyond its lead asset…
Earnings and financials
Aptevo Therapeutics Inc. (APVO) trades at $1.34, with a market cap of $2.93M and a trailing P/E of n/a. Revenue below is the annual history on file. It describes what the business has already reported. It is not a forecast and it is not a recommendation.
Insights · Dividends · Forecast · Financials · Learn